CardioVascular BioTherapeutics Appoints Grant Gordon to Vice Chairman of Board.International Investment Banking Veteran to Support CVBT's Efforts in Europe and Asia LAS VEGAS -- CardioVascular BioTherapeutics, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CVBT CVBT Cardiovascular Biotherapeutics, Inc CVBT Central Virginia Battlefields Trust (Fredericksburg, VA Civil War history organization) ), today announced that Grant Gordon has been named Vice Chairman of its Board of Directors. A member of CVBT's Board of Directors since 2005, Mr. Gordon has more than 28 years of international finance experience raising and managing private assets, as well as institutional investment management. Mr. Gordon's work has been primarily in the United Kingdom, Western Europe and Asia, where he spent 17 years. Since 1987, he has served as a Principal of GHL GHL Guideline Harvest Level (commercial fishing) GHL Greenland Halibut Financial Services Ltd., an international financial services group which co-founded CardioVascular BioTherapeutics in 1998, and has since arranged seed and venture capital for CVBT and other biotech entities. "Grant has provided valuable strategic counsel to CVBT and his knowledge of our industry and his financial services acumen make him ideally suited to serve as Vice Chairman," said Daniel C. Montano, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CardioVascular BioTherapeutics, Inc. "CardioVascular BioTherapeutics plans to commence clinical trials internationally with the goal to bring our protein therapies to market and Grant's experience and expertise in the European and Asian marketplaces will be instrumental in these efforts." CardioVascular BioTherapeutics is focused on the development of protein-based drugs for the treatment of cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease . The active ingredient in its drug candidates, CardioVascu-Grow(TM), contains a protein member of the fibroblast growth factor Fibroblast growth factors, or FGFs, are a family of growth factors involved in wound healing and embryonic development. The FGFs are heparin-binding proteins and interactions with cell-surface associated heparan sulfate proteoglycans have been shown to be essential for FGF family designed to stimulate the growth of new blood vessels Blood vessels Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names. , also known as angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. . The general principle is that once blood perfusion Blood perfusion A physiological term that refers to the process of nutritive delivery of arterial blood to a capillary bed in the biological tissue. Mentioned in: Interstitial Microwave Thermal Therapy is increased in the affected areas, patients with cardiovascular disease may experience improvement in tissue repair and function. "I am thrilled to be part of an already strong executive team, and look forward to accepting further responsibility on the Board as we move into the next phase of the company's growth," said Grant Gordon, Vice Chairman of the Board of Directors at CVBT. "I am honored to continue to represent the shareholders in my position as Vice Chairman, and excited to play a key role in expanding CVBT's international presence." About CardioVascular BioTherapeutics CVBT is a biopharmaceutical company developing drug candidates with Cardio Vascu-Grow[TM] as the active ingredient for a number of diseases characterized by inadequate blood flow to a tissue or organ. The company is currently conducting two FDA-authorized clinical trials: one in coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. in no-option heart patients, and one in impaired wound healing of the skin. Additionally, the company has completed pre-clinical studies in animal models of peripheral artery disease of the legs and stroke recovery. A foreign proof-of-concept clinical trial relating to chronic back pain believed to be caused by impaired or blocked lumbar arteries has been initiated. Cardio Vascu-Grow(TM) is a trademark of CardioVascular BioTherapeutics, Inc. This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, results of future clinical and pre-clinical trials, differences in patient outcomes, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion